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The  dysbetalipoproteinemia  is a  rare genetic  disorder  which  usually  requires  the  presence  of  a  metabolic
factor  for  expression  of their  phenotype.  We  report  a  patient  with  this  disease  in an  age  group  different
from  usual,  probably  triggered  by  a  postpartum  hypopituitarism.  This  association  is  described  in just  a
few case  reports  in  the medical  literature.
© 2015  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
España, S.L.U.  This  is an  open  access  article  under  the CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Síndrome  de  Sheehan  e  disbetalipoproteinemia:  uma  incomum  associac¸ ão
alavras-chave:
r  e  s  u  m  o
A  disbetalipoproteinemia  é uma  desordem  genética  rara  que usualmente  requer  a  presenc¸ a de  um fator
índrome de Sheehan
isbetalipoproteinemia
antoma palmar
metabólico  para  a expressão  do seu  fenótipo.  Reportamos  uma  paciente  com  esta  doenc¸ a em uma  idade
diferente  da  usual,  provavelmente  desencadeada  por  um  hipopituitarismo  pós-parto.  Esta  associac¸ ão tem
poucos  relatos  de  caso  na  literatura  médica.
©  2015  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
España,  S.L.U.  Este  é um  artigo  Open  Access  sob  a licença  de  CC BY-NC-NDntroduction
Genetic hyperlipidemias are relatively rare, but prompt recog-
ition and treatment can prevent serious complications, such as
therosclerosis. Multiple palmar xanthomas are essential to diag-
ose dysbetalipoproteinemia (type III hyperlipoproteinemia), an
ncommon genetic disorder of the lipoproteins metabolism.1 This
are disease is more frequent in men  than women, who  usu-
lly manifest it after menopause.2 We  describe a premenopausal
oman whose presenting features of dysbetalipoproteinemia were
riggered by postpartum hypopituitarism (Sheehan syndrome).∗ Corresponding author.
E-mail address: rafael radaeli@hotmail.com (R. de Figueiredo Radaeli).
http://dx.doi.org/10.1016/j.rpedm.2015.05.007
646-3439/©  2015  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Publ
icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Case report
A 39-year-old woman was referred to the endocrinology
outpatient clinic by severe hypercholesterolemia. She had an
episode of post partum hemorrhage eight years ago, and since
then reported chronic fatigue, weight gain and changes in men-
strual cycles. Her gynecologist reported oligomenorrheic cycles
during those years and amenorrhea for three consecutive months,
when ethinylestradiol plus cyproterone were prescribed. She was
taking these hormones in the last six months. She denied alcohol
abuse or cigarette smoking, and underwent cholecystectomy
for gallstones. Physical examination showed BMI  of 28.7 and
xanthomas striata palmaris on both hands (Panel A, Fig. 1). Xan-
thelasma palpebrarum was  not seen in her eyelids. All medications
were stopped, and a laboratory workup showed total cholesterol
(TC) of 15.51 mmol/L, and triglycerides (TG) of 21.18 mmol/L.
Lipoprotein electrophoresis depicted alpha lipoproteins
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PFig. 1. Panel A: skin lesions on the patient’s hand (xanthomas palmaris).
HDL) 11.2% (22.3–53.3%); pre-beta lipoproteins (VLDL) 51.9%
4.4–23.1%); beta lipoproteins (LDL) 36.9% (38.6–69.4%), con-
rming the diagnosis of dysbetalipoproteinemia. Blood glucose
evels, urinalysis, serum aspartate aminotransferase, and alanine
minotransferase were normal. Free thyroxine (T4): 1.67 pmol/L
6.94–15.95 pmol/L); cortisol: 16.55 nmol/L (149–690 nmol/L);
ollicular stimulant hormone (FSH): 2.66 IU/L (23–116 IU/L);
uteinizing hormone (LH): 0.59 IU/L (15.90–54 IU/L); prolactin:
.9 g/L (1.9–25 g/L); growth hormone (GH): <0.02 mg/L
<5 mg/L); IGF-1: 65.3 g/L (101–267 g/L); ACTH: 1.98 pmol/L
2.2–13.2 pmol/L). Sella turcica magnetic resonance image (MRI)
as normal. A hormonal proﬁle after insulin plus TRH (thyrotropin
eleasing hormone) plus GnRH (gonadotropin-releasing hormone)
as carried out; although hypoglycemia has not been obtained,
he test was highly suggestive of pituitary hormonal deﬁciencies
Panel B, Table 1). Transvaginal ultrasound showed uterus and
varies compatible with the patient’s age. Echocardiogram showed
ild hypertrophy of the left ventricule and mild mitral insufﬁ-
iency. Doppler of carotid arteries did not show any signiﬁcant
bnormalities. She was treated with levothyroxine 88 mcg/day,
rednisone 5 mg/day, atorvastatin 40 mg/day, and ciproﬁbrate
00 mg/day. After six months of follow-up, there was clinical
mprovement, complete resolution of the xanthomas palmaris and
arked improvement of the lipid proﬁle (TC: 4.06 mmol/L; HDL:
.42 mmol/L; LDL: 1.52 mmol/L; TG: 2.44 mmol/L).
ommentary
Dysbetalipoproteinemia is a rare lipid disorder character-
zed by high levels of serum cholesterol and triglycerides.1–3holesterol levels usually range from 300 to 600 mg/dL. Triglyc-
rides concentrations are usually greater than 400 mg/dL and may
xceed 1000 mg/dL. HDL cholesterol levels may  be normal or
ecreased. The disorder develops because both, a decreased ability
able 1
anel B: hormonal proﬁle after TRH plus GnRH plus insulin infusion.
Hormones GH (mg/L) FSH (IU/L) LH (IU/L) TSH (mIU/
Time
Basal 0.02 2.66 0.59 0.17 
45  min  0.02 2.71 0.71 0.46 
60  min  0.02 2.81 0.82 0.63 
90  min  0.02 2.94 0.91 0.50 
120  min  0.02 3.16 0.97 0.41 
180  min  0.02 3.21 0.92 0.29 inol Diabetes Metab. 2016;11(1):45–47
to convert very low-density lipoprotein (VLDL) and intermediate-
density lipoprotein (IDL) to low density lipoprotein (LDL)
particles in the blood, and a decreased clearance of chylomicron
remnants.2,4
Dysbetalipoproteinemia primarily affects older adults (men
more than women) and is rare in children and premenopausal
women.1 Estrogen therapy increases the clearance of VLDL rem-
nants, improving dysbetalipoproteinemia in some postmenopausal
women.
More than 90% of patients with dysbetalipoproteinemia are
homozygous for apoE2.5 Homozygosis for the apoE2 isoform occurs
at a frequency of about 1 in 100 in the general population.
Despite this high frequency, dysbetalipoproteinemia is relatively
rare, occurring in about 1 in 20 apoE2 homozygotes, with an overall
prevalence of 1 in 10,000.6,7
Clinical manifestations of this hyperlipoproteinemia appear to
require the presence of a secondary factor, such as a metabolic
derangement.6 It can be caused by lipoprotein overproduction syn-
dromes, such as obesity, diabetes mellitus, or alcohol abuse,4,5,8
or by disorders that further impair lipoprotein clearance, such as
hypothyroidism.5,6,8 In conditions characterized by VLDL overpro-
duction, the increased generation of remnant particles through
catabolism of VLDL overwhelms the ability to clear these remnants
from the plasma. Because the clinical manifestations are highly sen-
sitive to factors that increase hepatic lipoprotein production, this
disorder is usually responsive to therapeutic modalities directed at
decreasing hepatic lipoprotein production, such as dietary modiﬁ-
cations, weight loss, and alcohol consumption cessation.5
All patients with lipoprotein disorders should undertake a com-
prehensive clinical evaluation for the presence of corneal arcus,
corneal opaciﬁcation, xanthelasma palpebrarum, and xanthomas in
the extensor tendons, including palms, elbows, knees, and Achilles
tendons.9 Xanthomas are skin lesions that are present in more than
half of affected subjects. Xanthomas palmaris are orange-yellow
discolorations of the palmar creases, considered pathognomonic
for dysbetalipoproteinemia,4,7 but found in only 20% of patients.5
In the absence of palmar or tuberous xanthomas, the speciﬁc
diagnosis is more difﬁcult and requires lipoprotein electrophore-
sis to demonstrate the broad beta-band that denotes beta-VLDL.4
The VLDL cholesterol/triglycerides ratio is a useful screening test
as well; in type III hyperlipoproteinemia, when hyperlipidemia is
present, this ratio is usually greater than 0.3.4 The normal VLDL
cholesterol/triglycerides ratio is typically about 0.2.5
Dysbetalipoproteinemia accounts for 1.0% of the lipid disorders
associated with myocardial infarction.10 Thus, a careful history
should be obtained to ﬁnd out other modiﬁable risk factors for
atherosclerosis, such as smoking and hypertension. Peripheral vas-
cular disease is as prevalent as coronary artery disease in this
patient’s group.4 Because this disorder is most commonly autoso-
mal  recessive, there is often no family history of hyperlipidemia or
premature cardiovascular disease. First-degree relatives should be
screened for hyperlipidemia as well as have their risk stratiﬁed for
cardiovascular diseases.
Patients should be aggressively treated to decrease the risk
of cardiovascular disease.1 Dysbetalipoproteinemia has a good
L) Cortisol (nmol/L) Prolactin (g/L) Glucose (mmol/L)
17.10 1.47 4.995
28.69 2.27 4.773
18.20 2.09 4.218
19.86 1.70 4.218
20.41 1.56 4.495
21.24 1.67 4.218
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herapeutic response to lipid lowering agents. Drugs of choice
or severe hypertriglyceridemia include ﬁbric acid and high-dose
mega-3 fatty acids.1 Although statins are not the drugs of choice
o treat dysbetalipoproteinemia, their use may  be necessary if the
esponse to a ﬁbrate is poor.
We  describe a patient in that a careful history and physical
xamination were essentials to make the correct diagnosis and
o identify the underling etiology of dysbetalipoproteinemia. Xan-
homa striata palmaris is pathognomonic and can be the only
pparent sign of a potentially ominous disease.11 Thus, its clin-
cal recognition is paramount, and should direct the work-up
or dysbetalipoproteinemia.6 The obstetric history of this patient
uggested the diagnosis of Sheehan syndrome, hypopituitarism
ith cortisol and growth hormone deﬁciencies, and secondary
ypothyroidism. These hormonal deﬁciencies could have accel-
rated systemic atherosclerosis.3 She was treated with hormonal
eplacement therapy, atorvastatin, and ciproﬁbrate with improve-
ent of the lipid proﬁle. As a premenopausal woman  she has
eveloped this disease in an unusual age. As far as we  known,
here are only two case reports in the literature with the association
f Sheehan syndrome and dysbetalipoproteinemia.3,7 Despite our
atient had no known cardiovascular disease, she was  encouraged
o begin an aerobic exercise program and to engage a healthy diet
riented by a certiﬁed nutritionist.
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